Resolution to Approve the Prothena Business Demerger Passed at Elan EGM
Resolution to Approve the Prothena Business Demerger Passed at Elan EGM
DUBLIN--(BUSINESS WIRE)-- Elan Corporation, plc (NYS: ELN) announces that, at an Extraordinary General Meeting (EGM) held earlier today, the sole ordinary resolution to approve the demerger of the Prothena Business was duly passed. The full text of the resolution was included in the notice of the EGM dated November 12, 2012 which is available on the Company's website. The details of the votes lodged by proxy are also available on www.elan.com
About Elan
Elan Corporation, plc (NYS: ELN) is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. Elan shares trade on the New York and Irish Stock Exchanges. For additional information about the Company, please visit www.elan.com.
###
Investor Relations:
Chris Burns
Ph: 1-800-252-3526
or
David Marshall
Ph: + 353-1-709-4444
or
Media Relations:
Emer Reynolds
Ph: + 353-1-709-4022
or
Jonathan Birt
Ph: + 44-751-559-7858
KEYWORDS: United States Europe North America New York Ireland
INDUSTRY KEYWORDS:
The article Resolution to Approve the Prothena Business Demerger Passed at Elan EGM originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
